Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Zovirax (1)

2C-x series (1) · Analgesic (2) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Psychedelic (1) · [[:Category:Anti-herpesvirus_agents|Anti-herpesvirus agent]] (1) · [[:Category:Antivirals|Antiviral]] (1) · [[:Category:Nucleoside_analogs|Nucleoside analog]] (1)

None (1) · 5-HT2A partial agonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000909-QINU`"', '"`UNIQ--vote-0000090A-QINU`"', '"`UNIQ--vote-0000090B-QINU`"', '"`UNIQ--vote-0000090C-QINU`"', '"`UNIQ--vote-0000090D-QINU`"', '"`UNIQ--vote-0000090E-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days (1)

None (2) · 200, 400, 800 mg tablets; 200 mg capsules; 200 mg/5 mL suspension; 500, 1000 mg IV vials; 5% cream and ointment (topical) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · Indication-specific; high-dose IV regimens for encephalitis or disseminated disease (1)

None (1) · insufflated (1) · IV (1) · Oral (2) · PO (only formulation marketed in the US). (1) · PR (1) · topical (1)

None (1) · 30–60 min (PO) (1) · 45-75 min (oral) (1) · Symptom relief within 24-48 hours of starting episodic treatment (1)

None (1) · 4-8 h (1) · 4–6 hours (1) · 8 hours per oral dose (1)

None (1) · 2.5–3 hours (1) · Not well characterized (1) · ~3 hours; significantly prolonged in renal impairment'"`UNIQ--ref-0000090F-QINU`"' (1)

None (1) · Not well characterized (1) · ~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not established (1) · Widely used in pregnancy for HSV/VZV indications; reassuring registry data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)